ABBV - Abbvie Inc
(NaN%)
SNP 500
Sell
Weak Growth●Stock Price Very High
39%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 0.72%
Operating Income Growth is -8.24%
Net Income Growth is -21.43%
Earnings Per Share (EPS) Growth is -21.1%
Net Margin is 9.17%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 0.65
Debt Ratio is 0.53
Current Debt to Net Income Ratio is 8.1
Total Debt to Total Assets Ratio is 0.5
Cash Flow is MODERATE
Cash from Operations Growth is -35.29%
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Abbvie Inc (ABBV) - https://www.abbvie.com/
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.Exchange - NEW YORK STOCK EXCHANGE INC.
Industry - Research and Development in Biotechnology (except Nanobiotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Richard Gonzalez
Employees - 50,000
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.